Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 2A-B (Cert # L209131)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 08/19/2020
Content Release Date: 09/16/2020
Expiration Date: 03/16/2021
Activity Type: Application-based
CE Credits: 8.0 hours (BPS and ACPE)
Activity Fee: $160 (ASHP member); $215 (non-member)

Accreditation for Pharmacists

American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

These recertification activities are intended for board-certified pharmacists seeking to update their knowledge and skills in:

  • Acute Lymphoblastic Leukemia
  • Hematopoietic Stem Cell Transplantation
  • Colorectal Cancer
  • Melanoma
  • Lung
  • Lymphomas
  • Head and Neck

Activity Overview

The Home Study Syllabus is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.

Learners will be required to review the content of the articles and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS. 

For full program information, please visit: http://rxcertifications.org

Recertification Credit*

Board certified pharmacists are eligible to receive up to 8.0 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

Oncology Home Study Syllabus Module 2A: Acute Lymphoblastic Leukemia, Hematopoietic Stem Cell Transplantation, Colorectal Cancer

0204-9999-20-618-H01-P

4.00

83%

Oncology Home Study Syllabus Module 2B: Melanoma and Cutaneous Malignancies, Lung Cancer, Lymphomas, Head and Neck Cancer

0204-9999-20-934-H01-P

4.00

77%


Articles and Learning Objectives

Oncology Home Study Syllabus Module 2A: Acute Lymphoblastic Leukemia, Hematopoietic Stem Cell Transplantation, Colorectal Cancer

0204-9999-20-933-H01-P

Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 [published correction appears in Blood. 2019; 134:1111]. Blood. 2019; 133:1548-59.

Learning Objectives:

  • Interpret efficacy and safety data for a treatment regimen used in acute lymphoblastic leukemia.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan for patients with acute lymphoblastic leukemia.
  • Choose appropriate strategies for managing adverse events associated with a treatment regimen used in acute lymphoblastic leukemia.

Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322:123-33.

Learning Objectives:

  • Evaluate the efficacy of recombinant zoster vaccine for prevention of herpes zoster following autologous stem cell transplant in adult patients.
  • Counsel patients on toxicities of recombinant zoster vaccine in adults after autologous stem cell transplant.
  • Interpret statistical analyses to determine the efficacy of vaccines in clinical trials.

Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019; 381:1632-43.

Learning Objectives:

  • Apply the outcomes of the BEACON CRC trial to patients with BRAF-mutated advanced colorectal cancer.
  • Compare and contrast the experimental triplet-therapy (encorafenib, binimetinib, and cetuximab) with the experimental doublet-therapy (encorafenib and cetuximab).
  • Predict toxicities associated with the regimens studied in the BEACON CRC trial in order to effectively counsel patients.

Oncology Home Study Syllabus Module 2B: Melanoma and Cutaneous Malignancies, Lung Cancer, Lymphomas, Head and Neck Cancer
0204-9999-20-934-H01-P

Regan MM, Werner L, Rao S et al. Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition – a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2019; 37:3350-8.

Learning Objectives:

  • Apply the end point of “treatment-free survival” to patients with advanced melanoma receiving immune checkpoint inhibitor therapy.
  • Formulate counseling points for patients with advanced melanoma and their care teams regarding single-agent and combination therapy with immune checkpoint inhibitors.
  • Describe the adverse effect profile of immune checkpoint inhibitors when given as single agents and as combinations in patients with advanced melanoma.

Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019; 381:2020-31.

Learning Objectives:

  • Choose appropriate therapy for patients with advanced non-small cell lung cancer based on the results of the CheckMate 227 trial.
  • Analyze the efficacy and safety data for the use of combination ipilimumab/nivolumab to treat patients with advanced non-small cell lung cancer.
  • Select appropriate supportive care and monitoring for patients treated with the regimens used in CheckMate 227.

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380:45-56.

Learning Objectives:

  • Interpret efficacy and safety data for the use of tisagenlecleucel in diffuse large B-cell lymphoma.
  • Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes for patients with diffuse large B-cell lymphoma who receive tisagenlecleucel.
  • Assess the prognostic impact of relevant cancer-related molecular biology testing.

Zhang Y, Chen L, Hu GQ et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019; 381:1124-35.

Zhang Y, Chen L, Hu GQ et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019; 381(suppl):S1-22.

Learning Objectives:

  • Assess the outcomes and toxicity differences of induction chemotherapy versus standard combined chemoradiotherapy and its place in therapy for nasopharyngeal carcinoma.
  • Apply the results of this study to a patient with nasopharyngeal carcinoma.
  • Develop counseling points and supportive care recommendations for patients undergoing induction chemotherapy followed by cisplatin and radiation.

Planners, Presenters and Reviewers

Courtney C. Cavalieri, Pharm.D., BCOP
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah 
Assistant Professor of Pharmacy Practice, Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, University of Pittsburgh Medical Center at Passavant
Pittsburgh, Pennsylvania

Clinical Oncology Pharmacist
Oncology Clinical Coordinator
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Clinical Pharmacy Specialist
Spectrum Health
Grand Rapids, Michigan

Manager of Clinical Pharmacy Services/Clinical Oncology Pharmacist
Alvin J. Siteman Cancer Center/Washington University School of Medicine
St. Louis, Missouri

Hematology/Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York
Christine M. Walko, Pharm.D., FCCP, BCOP
Personalized Medicine Specialist
H. Lee Moffitt Cancer Center
DeBartolo Family Personalized Medicine Institute
Associate Professor - Department of Oncologic Sciences
USF Morsani College of Medicine
Tampa, Florida
Courtney C. Cavalieri, Pharm.D., BCOP
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
Associate Professor of Pharmacy Practice, Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, University of Pittsburgh Medical Center at Passavant
Pittsburgh, Pennsylvania
Danielle Roman, Pharm.D., BCOP
Manager - Clinical Pharmacy Services
Allegheny Health Network Cancer Institute
Pittsburgh, Pennsylvania
Associate Member, Individualized Cancer Management
H. Lee Moffitt Cancer Center
Tampa, Florida

Angela T. Cassano, Pharm.D., BCPS, FASHP
Susan R. Dombrowski, M.S., R.Ph.

Kyle Adkins, Pharm.D. BCOP, BCPS
Rama Al Ghannam, Pharm.D., BCOP
Kejal Amin, Pharm.D., MBA, BCOP
Robert Appell, Pharm.D., BCOP
Megan Ayala, Pharm.D., BCOP, MBA
Christopher Campbell, Pharm.D., BCPS, BCOP
Juhyang Cheon, BCOP
Eunah Cho, Pharm. D., BCOP
Jamey Groff, Pharm.D., BCOP
Elisabeth Hébert, B.Pharm., M.Sc., BCOP
Ying Shi Ho, Pharm.D., BCPS, BCOP
Anna Jan, Pharm.D., BCOP
Jocelyn Joseph, Pharm.D., BCOP
Amy Kamien, Pharm.D., BCOP
Ibrahim Lala, Pharm.D., BCPS, BCOP
Whitney Lewis, Pharm.D., BCOP
Valerie Lindeborg, Pharm.D., BCOP, BCSCP
Samantha Luk, Pharm.D., BCOP
Jonathan Malara, Pharm.D., BCOP
Anli McCoy, Pharm.D., BCOP
Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Mostafa Morsy, B.Pharm., Pharm.D., BCOP
Valerie Muthig , Pharm.D., BCOP
Annie Pellegrino, Pharm.D., BCOP
Laura Poggi, Pharm.D., BCOP
Muamer Ramic, Pharm.D., BCOP
Hope Schenk, Pharm.D., BCOP
Khurram Shahzad, Pharm.D., BCOP
Kaylee Shin, Pharm.D., BCOP
Shayna Simon, Pharm.D.
Sunao Slayton, Pharm.D., BCOP
Anne Spengler, Pharm.D., BCOP
Alison Stauder, Pharm.D., BCOP
Ajoke Tijani, Pharm.D., BCOP
Tara Tsukamoto, Pharm.D., BCOP
Deanne Williams, B.S.Pharm., BCOP
Lily Yan, Pharm.D., BCOP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Christine M. Walko, Consultant, Foundation Medicine; MTB Consultant, Jackson Genetic Laboratories; MTB Consultant, Intermountain Healthcare
  • Karen M. Fancher, Consultant, AstraZeneca, LP

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP.